Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Schweins, Brad Crutchfield

Thomas Schweins has been appointed as head of the life science business area for Qiagen, CEO Peer Schatz noted in an earnings call this week. Schweins has been with Qiagen since 2004 and has been an integral part of the company's executive committee during this period, Schatz said. He also previously served as head of marketing and strategy at Qiagen, where he was involved in managing the company's global life science business. He also previously worked for Boston Consulting Group, Hoechst, and Aventis.

Schweins is taking over for Brad Crutchfield, who stepped down from the role for personal reasons, Schatz said.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.